Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers
Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers
复制标题
DOI：
10.1038/s41416-020-0811-0
复制
发表时间：
2020-03-25
影响因子：
8.8
通讯作者：
Baba, Hideo
中科院分区：
文献类型：
--
作者：
Okadome, Kazuo;Baba, Yoshifumi;Baba, Hideo
PD-1/PD-L1通路在肿瘤免疫学中起着关键作用，并作为基于免疫的治疗靶点。关于PD-1的另一种配体PD-L2及其与人类癌症临床结果的关系知之甚少。方法应用免疫组化方法检测437例手术切除食管癌和100例内镜切除食管癌（鳞癌483例，腺癌36例，其他18例）中PD-L2和PD-L1的表达。结果PD-L2阳性组总生存率（n = 16.2%）低于PD-L2阴性组（n = 366，83.8%）（P = 0.011，log-rank检验）。PD-L2和PD-L1表达之间无显著相关性。多重免疫荧光显示PD-L2和PD-L1的表达模式存在变异性。在早期肿瘤中，与PD-L1相比，PD-L2表达更常见。结论PD-L2和PD-L1与食管癌的不良预后相关，支持PD-L2作为预后生物标志物的作用。考虑到PD-L2和PD-L1在表达时间和对化疗药物的反应方面具有不同的特征，评价PD-L2和PD-L1表达可能具有临床重要性。
Background The PD-1/PD-L1 pathway plays critical roles in tumour immunology, and serves as an immune-based therapeutic target. Less is known regarding PD-L2, another ligand of PD-1, and its relation to clinical outcome in human cancers. Methods We used a database of 437 surgically and 100 endoscopically resected oesophageal cancers (squamous cell carcinoma, n = 483; adenocarcinoma, n = 36; others, n = 18) to evaluate PD-L2 and PD-L1 expression by immunohistochemistry. Results Compared with PD-L2-negative cases (n = 366, 83.8%), PD-L2-positive cases (n = 71, 16.2%) had worse overall survival (P = 0.011, log-rank test). There was not a significant correlation between PD-L2 and PD-L1 expression. Multiplex immunofluorescence revealed that there was variability in the expression pattern of PD-L2 and PD-L1. In early-stage tumours, PD-L2 expression was more frequently observed compared with PD-L1. Conclusions PD-L2 as well as PD-L1 were associated with an unfavourable prognosis in oesophageal cancer, supporting the role of PD-L2 as a prognostic biomarker. Considering that PD-L2 and PD-L1 had different features in terms of expression timing and responses to chemotherapeutic drugs, evaluation of both PD-L2 and PD-L1 expression may be clinically important.